A5011225686- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- HIV-related health complications and treatments
- Fibroblast Growth Factor Research
- Bone health and treatments
- Systemic Sclerosis and Related Diseases
- Vaccine Coverage and Hesitancy
- Hepatitis C virus research
- Vestibular and auditory disorders
- Hearing, Cochlea, Tinnitus, Genetics
- Empathy and Medical Education
- Pneumocystis jirovecii pneumonia detection and treatment
- Hearing Loss and Rehabilitation
- Lipoproteins and Cardiovascular Health
- Mental Health and Patient Involvement
- Diabetes, Cardiovascular Risks, and Lipoproteins
Janssen (Italy)
2015-2023
Janssen (Switzerland)
2016-2022
Luigi Sacco Hospital
2021
University of Milan
2021
Azienda Ospedaliera Ospedale Civile di Legnano
2021
Vita-Salute San Raffaele University
2021
Istituti di Ricovero e Cura a Carattere Scientifico
2021
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2021
Aziende Socio Sanitarie Territoriale Ovest Milanese
2021
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
2021
Current antiretroviral (ARV) therapy for the treatment of human immunodeficiency virus (HIV-1)-infected patients provides long-term control viral load (VL). Darunavir (DRV) is a nonpeptidomimetic protease inhibitor approved use with ritonavir booster (DRV/r). This study evaluated effectiveness DRV/r in combination other ARV agents routine clinical practice Italy. In this descriptive observational study, data on utilization DRV/r, under conditions described marketing authorization, were...
Antiretroviral therapy (ART) significantly reduced Human Immunodeficiency Virus (HIV) morbidity and mortality; nevertheless, stigma still characterises the living with this condition. This study explored patients' coping experience by integrating narrative medicine (NM) in a non-interventional clinical trial. From June 2018 to September 2020 involved 18 centres across Italy; enrolled patients were both D/C/F/TAF naïve previously ART-treated. Narratives collected at enrolment (V1) last visit...
Introduction A regimen with rilpivirine (RPV), abacavir (ABC) and lamivudine (3TC) is simple may allow the sparing of tenofovir protease inhibitors. However, data on use this combination as a strategy switch are limited. Aims study were to assess long-term efficacy safety regimen. Methods Retrospective HIV-1 infected patients followed at Infectious Disease Department San Raffaele Scientific Institute, HBsAg-negative, HLA B5701-negative, no documented resistance RPV, ABC 3TC, HIV-RNA<50...
Background: The protease inhibitor (PI) darunavir (DRV) has proven to be highly effective and well tolerated for HIV treatment. DAD (Data collection on Adverse Effects of Anti-HIV Drugs) cohort showed an increased 5-year cumulative cardiovascular (CV) risk in patients given various PIs, including DRV, whereas two other recent studies found no association between DRV CV diseases. Methods: We performed a post-hoc analysis adverse events (CVAEs) Italian cohort, the TMC114-HIV4042 observational...
Introduction This descriptive, non‐interventional study on HIV‐1‐infected patients treated with DRV/r in the usual clinical setting, a single‐arm prospective observational design, collected data utilization of darunavir/ritonavir (DRV/r) under conditions described marketing authorization practice Italy to evaluate efficacy and safety DRV/r‐based antiretroviral (ARV) treatment. analysis focussed profile HIV‐1 infected patients. Materials Methods Data were analyzed from four cohorts real‐world...
Background We aimed to comparatively assess darunavir/ ritonavir (DRV/r) and efavirenz (EFV)-based first-line cART regimens in the reconstitution of T-cell phenotype function HIV-infected, late presenter subjects. Methods Retrospective, ex vivo study on stored peripheral blood mononuclear cell samples cART-naive, HIV-infected individuals with CD4 + counts <50>250/μl upon initiation either DRV/r or EFV as third drugs standard antiretroviral regimens. CD8 maturation (CCR7/CD45RA)...
Objective: This study investigates the effectiveness and tolerability of switching to a darunavir/cobicistat (DRV/c)-based antiretroviral regimen from ritonavir-boosted protease inhibitor (PI/r)-based in virologically suppressed HIV-positive patients. DRV trough values were also investigated. Setting: Prospective, multicenter, single-country, noninterventional cohort study. Methods: included patients on PI/r-based ART for at least 12 months having plasma HIV-1 RNA <50 copies/mL since 6...
This prospective, multicenter, non-interventional cohort study enrolling human immunodeficiency virus (HIV)-1-infected, virally suppressed adult outpatients in Italy aimed to describe results obtained from patient-reported outcome questionnaires regarding treatment satisfaction and symptom perceptions HIV-1-positive patients who switched cobicistat-boosted darunavir antiretroviral regimens, coming ritonavir-boosted protease inhibitors. Patients entered this between June 2016 February 2017,...
This was a descriptive non-interventional study in HIV-1-infected patients treated with DRV/r conducted the clinical setting, single-arm prospective design. The primary objective to collect data on utilization of darunavir/ritonavir (DRV/r) under conditions described marketing authorization. Efficacy (measured as viral load [VL] <50 copies/mL and CD4+ cell count) evaluated for combination other antiretroviral (ARV) agents routine practice Italy.Here we describe an analysis effectiveness...
Aim: DIAMANTE is a retrospective and prospective, non-interventional, cohort study to describe the effectiveness of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in real clinical practice Italy. Patients & methods: The enrolled 246 patients: group 1 included patients treated with darunavir-based regimen (n = 81); 2 who received antiretroviral treatment not including darunavir before D/C/F/TAF 43); 3 naive 122). Effectiveness was evaluated as virological response at...
The primary objective of this study was to estimate the proportion people living with HIV (PLWH) who switched from a non-protease inhibitor (PI)-based regimen [integrase strand transfer (InSTI)-based or non-nucleoside reverse transcriptase (NNRTI)-based regimen] darunavir, cobicistat, emtricitabine, tenofovir alafenamide (D/C/F/TAF).This retrospective on PLWH treated non-PI in January 2017, D/C/F/TAF another antiretroviral therapy (ART) within November 2019. Follow-up start date until last...
Abstract Antiretroviral therapy (ART) significantly reduced Human Immunodeficiency Virus (HIV) morbidity and mortality; nevertheless, stigma still characterises the living with this condition. This study explored patients’ coping experience by integrating narrative medicine (NM) in a non-interventional clinical trial. From June 2018 to September 2020 involved 18 centres across Italy; enrolled patients were both D/C/F/TAF naïve previously ART-treated. Narratives collected at enrolment (V1)...